Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer cell cytotoxicity receptor 3 (NKp30) is a type I transmembrane glycoprotein and a member of the natural cytotoxicity receptor (NCR) family, primarily expressed on mature Natural Killer (NK) cells [UniProt P14770]. Encoded by the NCR3 gene, it functions as a potent activating receptor that triggers the lysis of tumor cells and virally infected cells. The receptor recognizes specific ligands, most notably B7-H6, which is frequently overexpressed on various cancer types—including lymphoma, leukemia, and several solid tumors—but is generally absent on healthy tissues [Brandt et al., 2009; PubMed 19528259]. In the context of haNK cells (high-affinity NK cells), which are engineered NK-92 cells, NKp30-mediated signaling is a critical component of the cell's anti-tumor machinery alongside engineered CD16 [ImmunityBio, 2024]. Binding of NKp30 to its ligands leads to the phosphorylation of ITAM-containing adapter proteins, initiating a signaling cascade that results in the degranulation of cytotoxic molecules like perforin and granzymes. This pathway is a major focus for developing adoptive cell therapies and bispecific engagers aimed at treating malignancies that evade traditional immunosurveillance [Kruse et al., 2014].
Activation of natural killer cell-mediated cytotoxicity and pro-inflammatory cytokine release (e.g., IFN-gamma) through ITAM-containing adapter proteins (CD3z or FcERIy) upon binding to tumor-associated ligands such as B7-H6 or BAG6 [UniProt P14770; Brandt et al., 2009].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cell cytotoxicity receptor 3 (NKp30) (NKp30).